Palvella Therapeutics

Palvella Therapeutics, Inc. is a rare disease biopharmaceutical company founded in 2015 in Pennsylvania, USA, by veterans of the life sciences and rare disease industries. The company is dedicated to serving patients with debilitating rare genetic disorders through the development and commercialization of transformative, pathogen-targeted therapies, although such therapies are not yet approved. Currently, they are advancing the development of treatments for rare diseases such as Pachyonychia Congenita (PC) and Gorlin Syndrome. The company’s lead candidate drug, PTX-022 (QTORIN™ Rapamycin), is primarily being developed to treat patients with Pachyonychia Congenita.